AMSBIO to revolutionize Korea’s diagnostic market with saliva-based cancer diagnosis technology

South Korean In Vitro Diagnostics (IVD) medical device, and diagnostic reagent developer, AMSBIO is looking forward to building a new cancer diagnosis kit based on saliva testing. 

During the pandemic, South Korea’s IVD market went through many changes. It is anticipated that the IVD market will go up by a compound annual growth rate (CAGR) of 5.42 percent this year. 

Additionally, the demand for new technology in the laboratory and biotech sector is also rapidly rising in the pre-pandemic times. The burden of chronic diseases is increasing at a fast pace. There is more use of point-of-care diagnostics, and overall more awareness and acceptance of personalized medicines. 

In 2020, the country recorded more than 3 million diabetes cases. Whereas, cancer patients in South Korea crossed 230,000. In such scenarios, IVD needs to play a vital function in the world of healthcare.

Founded in 2000, AMSBIO has come a long way in making progress in securing new healthcare technology. It has been carrying on its mission to be a premium provider of life science research reagents and services. AMSBIO is overseen by its parent corporation Biosmart Co Ltd, a group that’s engaged in manufacturing stripe cards, memory and microprocessor smart cards in South Korea. 

The new initiatives of developing a saliva-based diagnosis technology are thought to change the IVD industry positively as saliva testing is fairly new to the South Korean marketplace. These kinds of PCR testing are uncommonly used in healthcare spaces mainly due to inaccuracy factors.  

The IVD firm’s coronavirus testing kits recently got a green light from the South Korean government’s food and drug safety ministry. These testing kits are different from other kits in the foreign and Korean markets as these work by just sharing the saliva samples and without nasopharyngeal or throat swabs.  

Saliva PCR kits are feasible options for testing where DNA gets amplified similarly to regular PCR. Nasal swabs are very much uneasy for most users while saliva testing has no such issues. 

Normally PCR tests take a lot of time and patients have no option but to wait for their test results. But this can be eliminated with the launching of new saliva-based testing kits because they exhibit results as quickly as 30 minutes or so.  

The biggest problem with the diagnosis kit is its level of genuineness. To counterbalance that question, AMSBIO is running trials to prove the authenticity of its saliva-based testing kits or products. 

The IVD firm AMSBIO perceives that the introduction of saliva-based PCR test kits for cancer will open the door for more opportunities in the IVD market. In the coming years, AMSBIO will be developing additional advanced technology or solutions for rapid diagnosis and testing processes. 

AMSBIO will be launching kits that not only do single testing but detects multiple other diseases as well. From covid-19 to flu and respiratory syncytial virus (RSV), the company will be bringing up a bunch of test kit solutions in the IVD industry.